AU2022430428A1 - Angiogenesis inhibitor-conjugated anti-c3b antibody or anti-c5 antibody and use thereof - Google Patents

Angiogenesis inhibitor-conjugated anti-c3b antibody or anti-c5 antibody and use thereof Download PDF

Info

Publication number
AU2022430428A1
AU2022430428A1 AU2022430428A AU2022430428A AU2022430428A1 AU 2022430428 A1 AU2022430428 A1 AU 2022430428A1 AU 2022430428 A AU2022430428 A AU 2022430428A AU 2022430428 A AU2022430428 A AU 2022430428A AU 2022430428 A1 AU2022430428 A1 AU 2022430428A1
Authority
AU
Australia
Prior art keywords
seq
protein
nonenglishqualifier
qualifiers
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022430428A
Other languages
English (en)
Inventor
Jihoon Chang
Eu Ddeum CHUNG
Donggeon Kim
Byoung Chul Lee
Soomin RYU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kanaph Therapeutics Inc
Original Assignee
Kanaph Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanaph Therapeutics Inc filed Critical Kanaph Therapeutics Inc
Publication of AU2022430428A1 publication Critical patent/AU2022430428A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2022430428A 2022-01-05 2022-12-27 Angiogenesis inhibitor-conjugated anti-c3b antibody or anti-c5 antibody and use thereof Pending AU2022430428A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2022-0001647 2022-01-05
KR1020220001647A KR20230105972A (ko) 2022-01-05 2022-01-05 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
PCT/KR2022/021371 WO2023132547A1 (ko) 2022-01-05 2022-12-27 혈관신생 억제제가 결합된 항-c3b 항체 또는 항-c5 항체 및 이의 용도

Publications (1)

Publication Number Publication Date
AU2022430428A1 true AU2022430428A1 (en) 2024-07-04

Family

ID=87073766

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022430428A Pending AU2022430428A1 (en) 2022-01-05 2022-12-27 Angiogenesis inhibitor-conjugated anti-c3b antibody or anti-c5 antibody and use thereof

Country Status (7)

Country Link
US (1) US20250074974A1 (https=)
EP (1) EP4461745A4 (https=)
JP (1) JP2025501913A (https=)
KR (1) KR20230105972A (https=)
CN (1) CN118510799A (https=)
AU (1) AU2022430428A1 (https=)
WO (1) WO2023132547A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3189030A1 (en) * 2020-07-07 2022-01-13 Kanaph Therapeutics Inc. Fusion protein including complement pathway inhibitor and angiogenesis inhibitor and use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
JP4897690B2 (ja) 2004-10-12 2012-03-14 ジェネンテック， インコーポレイテッド 補体関連障害の予防および処置のためのＣＲＩｇポリペプチド
PL3167888T3 (pl) * 2006-03-15 2024-08-26 Alexion Pharmaceuticals, Inc. Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza
US10259860B2 (en) * 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
BRPI0812767A2 (pt) * 2007-06-07 2014-12-02 Genentech Inc Anticorpos para c3b e métodos para prevenção e tratamento de distúrbios associados ao complemento
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
CA3056248A1 (en) * 2017-03-22 2018-09-27 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
WO2019112958A1 (en) 2017-12-05 2019-06-13 Abbvie Biotherapeutics Inc. Abt-165 in combination with folinic acid, 5-fluorouracil, and irinotecan for the treatment of cancers
MA51147A (fr) 2017-12-13 2021-03-24 Regeneron Pharma Associations d'anticorps anti-c5 et utilisations associées
US20200115443A1 (en) * 2018-10-12 2020-04-16 Trican Biotechnology Co., Ltd Bi-functional fusion proteins and uses thereof
EP4308591A4 (en) * 2021-03-18 2025-04-02 Affilogic POLYPEPTIDES FOR COMPLEMENT INHIBITION

Also Published As

Publication number Publication date
CN118510799A (zh) 2024-08-16
KR20230105972A (ko) 2023-07-12
EP4461745A4 (en) 2025-07-02
US20250074974A1 (en) 2025-03-06
JP2025501913A (ja) 2025-01-24
WO2023132547A1 (ko) 2023-07-13
EP4461745A1 (en) 2024-11-13

Similar Documents

Publication Publication Date Title
AU2021254602B9 (en) Humanized anti-MUC1* antibodies
AU2024200395A1 (en) Trispecific and/or trivalent binding proteins for prevention or treatment of HIV infection
AU2025200735A1 (en) Low-viscosity antigen binding proteins and methods of making them
KR102161460B1 (ko) St2 항원 결합 단백질
AU2024200534A1 (en) Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
AU2017385274B2 (en) Fusion protein including BDNF
KR101601387B1 (ko) c-KIT 항체 및 이의 용도
CN111989345B (zh) 激活wnt信号传导的多价结合分子及其用途
CN110573528B (zh) 针对共刺激性tnf受体的双特异性抗原结合分子
KR101882366B1 (ko) 온코스타틴 m 수용체 항원 결합 단백질
HU229566B1 (en) Human monoclonal antibodies to ctla-4
KR102543878B1 (ko) 항-ｖｅｇｆ-ａ 및 항-ａｎｇ2 항체 및 이의 용도
KR20150030706A (ko) 이중 수용체 길항 항원-결합 단백질 및 그것의 사용
KR20210040378A (ko) 데코린을 포함하는 다기능 단백질 분자 및 이의 용도
AU2024202263A1 (en) Antibodies to PMEL17 and conjugates thereof
AU2022372527A1 (en) Antigen-binding protein comprising two fc domains and use thereof
KR20100057021A (ko) 신규한 항체
AU2023287212A1 (en) Antigen-binding molecule specifically binding to dll3 and cd3, and pharmaceutical use thereof
AU2022430428A1 (en) Angiogenesis inhibitor-conjugated anti-c3b antibody or anti-c5 antibody and use thereof
TW201223543A (en) Anti-VEGFR-3 antibody compositions
CN111295393B (zh) 靶向干细胞因子及半乳糖凝集素-1的双重靶向抗体及其用途
AU2023226293A1 (en) Medicine comprising combination of anti-mutant-calr antibody and another drug
KR20220006010A (ko) 보체 경로 억제제 및 혈관신생 억제제를 포함하는 융합단백질 및 이의 용도
TWI914375B (zh) 含有補體路徑抑制物及血管生成抑制物的融合蛋白及其用途
CN112794906B (zh) 抗4-1bb的单链抗体及其应用